Is ANRO or IKT more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -46.46% -39.09% Inhibikase Therapeutics N/A -42.80% -40.58%

Is IKT or SPTX more profitable?

Seaport Therapeutics' return on equity of 0.00% beat Inhibikase Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -42.80% -40.58% Seaport Therapeutics N/A N/A N/A

Do analysts recommend IKT or CALT?

Inhibikase Therapeutics currently has a consensus price target of $5.40, suggesting a potential upside of 133.77%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.00 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Inhibikase Therapeutics (IKT) Competitors

$2.31 -0.08 (-3.35%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$2.36 +0.04 (+1.95%)

As of 09/15/2026 07:30 PM Eastern

Compare

IKT vs. ANRO, SPTX, CRON, CALT, and PCRX

Should you buy Inhibikase Therapeutics stock or one of its competitors? Inhibikase Therapeutics's main competitors and comparable companies include Alto Neuroscience (ANRO), Seaport Therapeutics (SPTX), Cronos Group (CRON), Calliditas Therapeutics AB (publ) (CALT), and Pacira BioSciences (PCRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Inhibikase Therapeutics compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Alto Neuroscience currently has a consensus price target of $37.25, suggesting a potential upside of 23.03%. Inhibikase Therapeutics has a consensus price target of $5.40, suggesting a potential upside of 133.77%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Alto Neuroscience has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Inhibikase Therapeutics' return on equity of -42.80% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-46.46%	-39.09%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

Inhibikase Therapeutics has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Inhibikase Therapeutics	$260K	1,239.76	-$48.26M	-$0.43	N/A

In the previous week, Alto Neuroscience had 4 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 5 mentions for Alto Neuroscience and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.89 beat Alto Neuroscience's score of 0.42 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
Inhibikase Therapeutics	Very Positive

Summary

Inhibikase Therapeutics beats Alto Neuroscience on 10 of the 15 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Seaport Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Seaport Therapeutics (NASDAQ:SPTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Inhibikase Therapeutics has higher revenue and earnings than Seaport Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,239.76	-$48.26M	-$0.43	N/A
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

Seaport Therapeutics' return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Seaport Therapeutics	N/A	N/A	N/A

In the previous week, Seaport Therapeutics had 13 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 14 mentions for Seaport Therapeutics and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.89 beat Seaport Therapeutics' score of 0.85 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Inhibikase Therapeutics	Very Positive
Seaport Therapeutics	Positive

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Inhibikase Therapeutics currently has a consensus price target of $5.40, suggesting a potential upside of 133.77%. Seaport Therapeutics has a consensus price target of $37.33, suggesting a potential upside of 62.60%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Inhibikase Therapeutics is more favorable than Seaport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36

Summary

Inhibikase Therapeutics beats Seaport Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Cronos Group has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Cronos Group has a net margin of 39.08% compared to Inhibikase Therapeutics' net margin of 0.00%. Cronos Group's return on equity of 4.85% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	39.08%	4.85%	4.62%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

In the previous week, Cronos Group had 5 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 6 mentions for Cronos Group and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.89 beat Cronos Group's score of 0.91 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cronos Group	Positive
Inhibikase Therapeutics	Very Positive

Cronos Group has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59M	8.05	-$9.45M	$0.20	16.00
Inhibikase Therapeutics	$260K	1,239.76	-$48.26M	-$0.43	N/A

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cronos Group presently has a consensus price target of $2.30, indicating a potential downside of 28.13%. Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 133.77%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Cronos Group beats Inhibikase Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Calliditas Therapeutics AB (publ)?

Inhibikase Therapeutics (NASDAQ:IKT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Inhibikase Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Inhibikase Therapeutics' average media sentiment score of 1.89 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Inhibikase Therapeutics	Very Positive
Calliditas Therapeutics AB (publ)	Neutral

Inhibikase Therapeutics currently has a consensus price target of $5.40, suggesting a potential upside of 133.77%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Inhibikase Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Inhibikase Therapeutics' return on equity of -42.80% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Inhibikase Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,239.76	-$48.26M	-$0.43	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Inhibikase Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Summary

Inhibikase Therapeutics beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Pacira BioSciences?

Pacira BioSciences (NASDAQ:PCRX) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Pacira BioSciences has a net margin of 1.96% compared to Inhibikase Therapeutics' net margin of 0.00%. Pacira BioSciences' return on equity of 9.68% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	1.96%	9.68%	5.30%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Pacira BioSciences currently has a consensus price target of $29.83, indicating a potential upside of 23.89%. Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 133.77%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Pacira BioSciences had 7 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 8 mentions for Pacira BioSciences and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.89 beat Pacira BioSciences' score of 0.83 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Pacira BioSciences	Positive
Inhibikase Therapeutics	Very Positive

Pacira BioSciences has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.32	$7.03M	$0.35	68.80
Inhibikase Therapeutics	$260K	1,239.76	-$48.26M	-$0.43	N/A

Pacira BioSciences has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Summary

Pacira BioSciences beats Inhibikase Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Inhibikase Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IKT vs. The Competition

Export

Metric	Inhibikase Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$333.49M	$12.43B	$7.21B	$15.01B
Dividend Yield	N/A	2.63%	2.57%	12.21%
P/E Ratio	-5.37	789.61	272.84	25.31
Price / Sales	1,239.76	952.99	701.69	107.35
Price / Cash	N/A	89.50	77.71	51.48
Price / Book	1.00	10.41	10.37	6.18
Net Income	-$48.26M	$2.83B	$3.49B	$357.96M
7 Day Performance	-4.15%	-1.51%	-0.76%	-0.56%
1 Month Performance	-4.15%	0.80%	-0.39%	-3.62%
1 Year Performance	48.08%	3.96%	18.93%	6.05%

Inhibikase Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IKT Inhibikase Therapeutics	2.2981 of 5 stars	$2.31 -3.3%	$5.40 +133.8%	+44.4%	$333.49M	$260K	N/A	35
ANRO Alto Neuroscience	2.2931 of 5 stars	$35.65 +0.3%	$37.25 +4.5%	+706.3%	$1.40B	N/A	N/A	N/A	Analyst Downgrade
SPTX Seaport Therapeutics	2.8447 of 5 stars	$24.86 flat	$37.33 +50.2%	N/A	$1.33B	N/A	N/A	N/A	News Coverage Positive News
CRON Cronos Group	1.67 of 5 stars	$3.26 flat	$2.30 -29.4%	+25.5%	$1.20B	$146.59M	16.30	450	News Coverage
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IKT) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibikase Therapeutics (IKT) Competitors

IKT vs. ANRO, SPTX, CRON, CALT, and PCRX

How does Inhibikase Therapeutics compare to Alto Neuroscience?

Summary

How does Inhibikase Therapeutics compare to Seaport Therapeutics?

Summary

How does Inhibikase Therapeutics compare to Cronos Group?

Summary

How does Inhibikase Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Inhibikase Therapeutics compare to Pacira BioSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibikase Therapeutics (IKT) Competitors

IKT vs. ANRO, SPTX, CRON, CALT, and PCRX

How does Inhibikase Therapeutics compare to Alto Neuroscience?

Do analysts prefer ANRO or IKT?

Which has more risk & volatility, ANRO or IKT?

Do institutionals & insiders hold more shares of ANRO or IKT?

Is ANRO or IKT more profitable?

Which has better earnings and valuation, ANRO or IKT?

Does the media prefer ANRO or IKT?

Summary

How does Inhibikase Therapeutics compare to Seaport Therapeutics?

Which has higher earnings and valuation, IKT or SPTX?

Is IKT or SPTX more profitable?

Does the media refer more to IKT or SPTX?

Do institutionals and insiders hold more shares of IKT or SPTX?

Do analysts rate IKT or SPTX?

Summary

How does Inhibikase Therapeutics compare to Cronos Group?

Which has more volatility & risk, CRON or IKT?

Is CRON or IKT more profitable?

Does the media prefer CRON or IKT?

Which has preferable valuation & earnings, CRON or IKT?

Do institutionals & insiders believe in CRON or IKT?

Do analysts prefer CRON or IKT?

Summary

How does Inhibikase Therapeutics compare to Calliditas Therapeutics AB (publ)?

Does the media prefer IKT or CALT?

Do analysts recommend IKT or CALT?

Is IKT or CALT more profitable?

Which has preferable valuation and earnings, IKT or CALT?

Do insiders and institutionals hold more shares of IKT or CALT?

Which has more risk and volatility, IKT or CALT?

Summary

How does Inhibikase Therapeutics compare to Pacira BioSciences?

Is PCRX or IKT more profitable?

Do institutionals and insiders have more ownership in PCRX or IKT?

Do analysts prefer PCRX or IKT?

Does the media favor PCRX or IKT?

Which has stronger valuation and earnings, PCRX or IKT?

Which has more volatility and risk, PCRX or IKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools